The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer

BACKGROUND: Despite being widely used, to date (June 2021), the regimen of bevacizumab 10 mg/kg every 2 weeks (Q2W) combined with chemotherapy is not approved in Japan for patients with platinum-resistant recurrent ovarian cancer. In this retrospective analysis, we evaluated the usage patterns of be...

Descripción completa

Detalles Bibliográficos
Autores principales: Sekine, Masayuki, Enomoto, Takayuki, Watanabe, Yoh, Katabuchi, Hidetaka, Yaegashi, Nobuo, Aoki, Daisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520859/
https://www.ncbi.nlm.nih.gov/pubmed/34308512
http://dx.doi.org/10.1007/s10147-021-01996-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520859/
https://www.ncbi.nlm.nih.gov/pubmed/34308512
http://dx.doi.org/10.1007/s10147-021-01996-8

Ejemplares similares